Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury

doi:10.12114/j.issn.1007-9572.2024.0247

Abstract

Abstract:

Patients with post-COVID-19 condition (PCC) of myocardial injury may exhibit a variety of cardiac-related symptoms, such as palpitations, chest distress, chest pain, without objective evidence of cardiovascular disease. In recent years, PCC of myocardial injury, as a newly emerging condition, lacks evidence-based medical evidence to support its diagnosis and treatment. Insufficient clinical experience in the diagnosis and treatment can easily lead to prolonged illness and decreased quality of life in patients. Therefore, this article focuses on the latest research progress in the diagnosis, clinical treatment, and rehabilitation of PCC of myocardial injury and improves the knowledge of clinical workers about this disease.

Key words: COVID-19, Post-COVID-19 condition, Cardiomyopathies, Diagnosis and treatment, Review

摘要：

COVID-19后遗症（PCC）心肌损伤患者表现出心悸、胸闷、胸痛等多种心脏相关症状，但没有心血管疾病的客观证据。近年来，PCC心肌损伤作为一种新发病症，诊断和治疗缺乏循证医学证据支持。临床对该病症的诊疗经验不足，易导致患者病情迁延不愈，生活质量下降。因此，本文重点探讨PCC心肌损伤的诊断、临床治疗与康复的最新研究进展，提高临床工作者对这一疾病的认识。

关键词: 新型冠状病毒感染, COVID-19后遗症, 心肌疾病, 诊断与治疗, 综述

CHEN Yiping,ZHANG Jianmei,LI Yanhu, et al. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury[J]. Chinese General Practice, 2026, 29(18): 2585-2592. DOI: 10.12114/j.issn.1007-9572.2024.0247.
陈义萍,张剑梅,厉彦虎等. COVID-19后遗症心肌损伤的诊疗进展[J]. 中国全科医学, 2026, 29(18): 2585-2592. DOI: 10.12114/j.issn.1007-9572.2024.0247.

References 71

[1]	SORIANO J B, MURTHY S, MARSHALL J C, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus[J]. Lancet Infect Dis, 2022, 22(4): e102-e107. DOI: 10.1016/S1473-3099(21)00703-9.
[2]	WRITING COMMITTEE, GLUCKMAN T J, BHAVE N M, et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American college of cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2022, 79(17): 1717-1756. DOI: 10.1016/j.jacc.2022.02.003.
[3]	李发久, 朱紫阳, 陈实, 等. 新型冠状病毒肺炎相关心肌损伤的临床观察[J]. 武汉大学学报(医学版), 2021, 42(5): 698-703. DOI: 10.14188/j.1671-8852.2020.0375.
[4]	ANUPAMA B K, CHAUDHURI D. A review of acute myocardial injury in coronavirus disease 2019[J]. Cureus, 2020, 12(6): e8426. DOI: 10.7759/cureus.8426.
[5]	SHI S B, QIN M, SHEN B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China[J]. JAMA Cardiol, 2020, 5(7): 802-810. DOI: 10.1001/jamacardio.2020.0950.
[6]	GIUSTINO G, CROFT L B, STEFANINI G G, et al. Characterization of myocardial injury in patients with COVID-19[J]. J Am Coll Cardiol, 2020, 76(18): 2043-2055. DOI: 10.1016/j.jacc.2020.08.069.
[7]	SANDOVAL Y, JANUZZI J L Jr, JAFFE A S. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week[J]. J Am Coll Cardiol, 2020, 76(10): 1244-1258. DOI: 10.1016/j.jacc.2020.06.068.
[8]	GUO T, FAN Y Z, CHEN M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019(COVID-19)[J]. JAMA Cardiol, 2020, 5(7): 811-818. DOI: 10.1001/jamacardio.2020.1017.
[9]	WANG C W, CHUANG H C, TAN T H. ACE2 in chronic disease and COVID-19: gene regulation and post-translational modification[J]. J Biomed Sci, 2023, 30(1): 71. DOI: 10.1186/s12929-023-00965-9.
[10]	HUYNH T V, RETHI L, LEE T W, et al. Spike protein impairs mitochondrial function in human cardiomyocytes: mechanisms underlying cardiac injury in COVID-19[J]. Cells, 2023, 12(6): 877. DOI: 10.3390/cells12060877.
[11]	BAILEY A L, DMYTRENKO O, GREENBERG L, et al. SARS-CoV-2 infects human EngineeredHeart tissues and models COVID-19 myocarditis[J]. JACC Basic Transl Sci, 2021, 6(4): 331-345. DOI: 10.1016/j.jacbts.2021.01.002.
[12]	GYÖNGYÖSI M, ALCAIDE P, ASSELBERGS F W, et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases[J]. Cardiovasc Res, 2023, 119(2): 336-356. DOI: 10.1093/cvr/cvac115.
[13]	WRITING COMMITTEE, GLUCKMAN T J, BHAVE N M, et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American college of cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2022, 79(17): 1717-1756. DOI: 10.1016/j.jacc.2022.02.003.
[14]	LAI C C, HSU C K, YEN M Y, et al. Long COVID: an inevitable sequela of SARS-CoV-2 infection[J]. J Microbiol Immunol Infect, 2023, 56(1): 1-9. DOI: 10.1016/j.jmii.2022.10.003.
[15]	国家老年医学中心, 中国老年医学学会心电与心功能分会, 北京医学会心血管病学分会影像学组, 等. 新型冠状病毒感染相关心肌损伤、心肌炎和感染后状态管理专家共识(第二版)[J]. 中国全科医学, 2023, 26(14): 1692-1702. DOI: 10.12114/j.issn.1007-9572.2023.0083.
[16]	KNIGHT D S, KOTECHA T, RAZVI Y, et al. COVID-19: myocardial injury in survivors[J]. Circulation, 2020, 142(11): 1120-1122. DOI: 10.1161/CIRCULATIONAHA.120.049252.
[17]	HUANG L, ZHAO P J, TANG D Z, et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging[J]. JACC Cardiovasc Imaging, 2020, 13(11): 2330-2339. DOI: 10.1016/j.jcmg.2020.05.004.
[18]	KAPUSTA J, BABICKI M, PIENIAWSKA-ŚMIECH K, et al. Clinical and electrocardiographic correlates of myocardial dysfunction after COVID-19 in nonhospitalised patients in long-term follow-up. Data from the Polish long-covid cardiovascular study[J]. J Med Virol, 2023, 95(12): e29331. DOI: 10.1002/jmv.29331.
[19]	TAMAN, MAGEED N, ELMORSY M, et al. Heart rate variability as an indicator of COVID-19 induced myocardial injury: a retrospective cohort study[J]. BMC Anesthesiol, 2023, 23(1): 17. DOI: 10.1186/s12871-023-01975-8.
[20]	MOOREN F C, BÖCKELMANN I, WARANSKI M, et al. Autonomic dysregulation in long-term patients suffering from Post-COVID-19 Syndrome assessed by heart rate variability[J]. Sci Rep, 2023, 13(1): 15814. DOI: 10.1038/s41598-023-42615-y.
[21]	ALTERSBERGER M, GOLIASCH G, KHAFAGA M, et al. Echocardiography and lung ultrasound in long COVID and post-COVID syndrome, a review document of the Austrian society of pneumology and the Austrian society of ultrasound in medicine[J]. J Ultrasound Med, 2023, 42(2): 269-277. DOI: 10.1002/jum.16068.
[22]	YANG H, NEGISHI K, WANG Y, et al. Echocardiographic screening for non-ischaemic stage B heart failure in the community[J]. Eur J Heart Fail, 2016, 18(11): 1331-1339. DOI: 10.1002/ejhf.643.
[23]	LUETKENS J A, SCHLESINGER-IRSCH U, KUETTING D L, et al. Feature-tracking myocardial strain analysis in acute myocarditis: diagnostic value and association with myocardial oedema[J]. Eur Radiol, 2017, 27(11): 4661-4671. DOI: 10.1007/s00330-017-4854-4.
[24]	GHERBESI E, BERGAMASCHI L, CUSMANO I, et al. The usefulness of speckle tracking echocardiography in identifying subclinical myocardial dysfunction in young adults recovered from mild COVID-19[J]. Echocardiography, 2022, 39(9): 1190-1197. DOI: 10.1111/echo.15431.
[25]	FU H, ZHANG N, ZHENG Y L, et al. Risk stratification of cardiac sequelae detected using cardiac magnetic resonance in late convalescence at the six-month follow-up of recovered COVID-19 patients[J]. J Infect, 2021, 83(1): 119-145. DOI: 10.1016/j.jinf.2021.04.016.
[26]	国家心血管病专业质控中心心血管影像质控专家工作组. 中国心血管影像技术应用现状调查与医疗质量报告[J]. 中国循环杂志, 2020, 35(7): 625-633. DOI: 10.3969/j.issn.1000-3614.2020.07.001.
[27]	CROSIER R, KAFIL T S, PATERSON D I. Imaging for cardiovascular complications of COVID-19: cardiac manifestations in context[J]. Can J Cardiol, 2023, 39(6): 779-792. DOI: 10.1016/j.cjca.2023.01.022.
[28]	WANG R S, LOSCALZO J. Repurposing drugs for the treatment of COVID-19 and its cardiovascular manifestations[J]. Circ Res, 2023, 132(10): 1374-1386. DOI: 10.1161/CIRCRESAHA.122.321879.
[29]	FUNG K W, BAYE F, BAIK S H, et al. Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients[J]. JAMA Intern Med, 2023, 183(12): 1404-1406. DOI: 10.1001/jamainternmed.2023.5099.
[30]	ClinicalTrials.gov. RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms [EB/OL]. [2024-08-08].
[31]	ClinicalTrials.gov. imPROving Quality of LIFe In the Long COVID Patient[EB/OL]. [2024-08-08].
[32]	HE W, XU K, NI L, et al. Myocardial injury and related mortality in hospitalized patients with COVID-19 during the Omicron pandemic: new perspectives and insights[J]. Virol Sin, 2023, 38(6): 940-950. DOI: 10.1016/j.virs.2023.10.005.
[33]	ZHENG Y Y, MA Y T, ZHANG J Y, et al. COVID-19 and the cardiovascular system[J]. Nat Rev Cardiol, 2020, 17(5): 259-260. DOI: 10.1038/s41569-020-0360-5.
[34]	ClinicalTrials.gov. Stratified Medicine of Eplerenone in Acute MI/Injury[EB/OL]. [2024-08-08].
[35]	PETCHERSKI A, SHARMA M, SATTA S, et al. Mitoquinone mesylate targets SARS-CoV-2 infection in preclinical models[J]. bioRxiv, 2022: 2022.02.22.481100. DOI: 10.1101/2022.02.22.481100.
[36]	BARLETTA M A, MARINO G, SPAGNOLO B, et al. Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome[J]. Clin Exp Med, 2023, 23(3): 667-678. DOI: 10.1007/s10238-022-00871-8.
[37]	BOJKOVA D, KLANN K, KOCH B, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets[J]. Nature, 2020, 583(7816): 469-472. DOI: 10.1038/s41586-020-2332-7.
[38]	JIRAK P, VAN ALMSICK V, DIMITROULIS D, et al. Dexamethasone improves cardiovascular outcomes in critically ill COVID-19, a real world scenario multicenter analysis[J]. Front Med, 2022, 9: 808221. DOI: 10.3389/fmed.2022.808221.
[39]	CHOU C H, HUNG C S, LIAO C W, et al. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis[J]. Cardiovasc Res, 2018, 114(5): 690-702. DOI: 10.1093/cvr/cvy013.
[40]	MARIETTE X, HERMINE O, THARAUX P L, et al. Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial[J]. JAMA Intern Med, 2021, 181(9): 1241-1243. DOI: 10.1001/jamainternmed.2021.2209.
[41]	LEISMAN D E, RONNER L, PINOTTI R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes[J]. Lancet Respir Med, 2020, 8(12): 1233-1244. DOI: 10.1016/S2213-2600(20)30404-5.
[42]	CAVALLI G, LUCA G D, CAMPOCHIARO C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study[J]. Lancet Rheumatol, 2020, 2(6): e325-e331. DOI: 10.1016/S2665-9913(20)30127-2.
[43]	DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072. DOI: 10.1016/j.cell.2012.03.042.
[44]	YANG L, WU Y Y, JIN W D, et al. The potential role of ferroptosis in COVID-19-related cardiovascular injury[J]. Biomedecine Pharmacother, 2023, 168: 115637. DOI: 10.1016/j.biopha.2023.115637.
[45]	HAN Y L, ZHU J J, YANG L L, et al. SARS-CoV-2 infection induces ferroptosis of sinoatrial node pacemaker cells[J]. Circ Res, 2022, 130(7): 963-977. DOI: 10.1161/CIRCRESAHA.121.320518.
[46]	LIBBY P, LÜSCHER T. COVID-19 is, in the end, an endothelial disease[J]. Eur Heart J, 2020, 41(32): 3038-3044. DOI: 10.1093/eurheartj/ehaa623.
[47]	KELL D B, LAUBSCHER G J, PRETORIUS E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications[J]. Biochem J, 2022, 479(4): 537-559. DOI: 10.1042/BCJ20220016.
[48]	SYKES R A, NEVES K B, ALVES-LOPES R, et al. Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy[J]. Eur Heart J Cardiovasc Pharmacother, 2023, 9(4): 371-386. DOI: 10.1093/ehjcvp/pvad025.
[49]	ZIMMERMANN P, SOURIJ H, ABERER F, et al. SGLT2 inhibitors in long COVID syndrome: is there a potential role?[J]. J Cardiovasc Dev Dis, 2023, 10(12): 478. DOI: 10.3390/jcdd10120478.
[50]	HUANG C L, HUANG L X, WANG Y M, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study[J]. Lancet, 2023, 401(10393): e21-e33. DOI: 10.1016/S0140-6736(23)00810-3.
[51]	SKJØRTEN I, ANKERSTJERNE O A W, TREBINJAC D, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation[J]. Eur Respir J, 2021, 58(2): 2100996. DOI: 10.1183/13993003.00996-2021.
[52]	BUCKLEY B J R, HARRISON S L, FAZIO-EYNULLAYEVA E, et al. Exercise rehabilitation associates with lower mortality and hospitalisation in cardiovascular disease patients with COVID-19[J]. Eur J Prev Cardiol, 2022, 29(1): e32-e34. DOI: 10.1093/eurjpc/zwaa135.
[53]	MARON B J, UDELSON J E, BONOW R O, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American heart association and American college of cardiology[J]. Circulation, 2015, 132(22): e273-e280. DOI: 10.1161/CIR.0000000000000239.
[54]	SÁNCHEZ-GARCÍA J C, REINOSO-COBO A, PIQUERAS-SOLA B, et al. Long COVID and physical therapy: a systematic review[J]. Diseases, 2023, 11(4): 163. DOI: 10.3390/diseases11040163.
[55]	VAN DE VOOREN H, GADEMAN M G, SWENNE C A, et al. Baroreflex sensitivity, blood pressure buffering, and resonance: what are the links? Computer simulation of healthy subjects and heart failure patients[J]. J Appl Physiol, 2007, 102(4): 1348-1356. DOI: 10.1152/japplphysiol.00158.2006.
[56]	CORRADO J, IFTEKHAR N, HALPIN S, et al. HEART rate variability biofeedback for long COVID dysautonomia (HEARTLOC): results of a feasibility study[J]. Adv Rehabil Sci Pract, 2024, 13: 27536351241227261. DOI: 10.1177/27536351241227261.
[57]	BRAWNER C A, EHRMAN J K, BOLE, et al. Inverse relationship of maximal exercise capacity to hospitalization secondary to coronavirus disease 2019[J]. Mayo Clin Proc, 2021, 96(1): 32-39. DOI: 10.1016/j.mayocp.2020.10.003.
[58]	SCURATI R, PAPINI N, GIUSSANI P, et al. The challenge of long COVID-19 management: from disease molecular hallmarks to the proposal of exercise as therapy[J]. Int J Mol Sci, 2022, 23(20): 12311. DOI: 10.3390/ijms232012311.
[59]	MARTINEZ M W, TUCKER A M, BLOOM O J, et al. Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening[J]. JAMA Cardiol, 2021, 6(7): 745-752. DOI: 10.1001/jamacardio.2021.0565.
[60]	JIMENO-ALMAZÁN A, FRANCO-LÓPEZ F, BUENDÍA-ROMERO Á, et al. Rehabilitation for post-COVID-19 condition through a supervised exercise intervention: a randomized controlled trial[J]. Scand J Med Sci Sports, 2022, 32(12): 1791-1801. DOI: 10.1111/sms.14240.
[61]	BARBARA C, CLAVARIO P, MARZO V D, et al. Effects of exercise rehabilitation in patients with long coronavirus disease 2019[J]. Eur J Prev Cardiol, 2022, 29(7): e258-260. DOI: 10.1093/eurjpc/zwac019.
[62]	MOOREN J M, GARBSCH R, SCHÄFER H, et al. Medical rehabilitation of patients with post-COVID-19 syndrome-a comparison of aerobic interval and continuous training[J]. J Clin Med, 2023, 12(21): 6739. DOI: 10.3390/jcm12216739.
[63]	MCGREGOR G, POWELL R, BEGG B, et al. High-intensity interval training in cardiac rehabilitation: a multi-centre randomized controlled trial[J]. Eur J Prev Cardiol, 2023, 30(9): 745-755. DOI: 10.1093/eurjpc/zwad039.
[64]	CASONATTO J, GOESSLER K F, CORNELISSEN V A, et al. The blood pressure-lowering effect of a single bout of resistance exercise: a systematic review and meta-analysis of randomised controlled trials[J]. Eur J Prev Cardiol, 2016, 23(16): 1700-1714. DOI: 10.1177/2047487316664147.
[65]	MARZOLINI S, OH P I, BROOKS D. Effect of combined aerobic and resistance training versus aerobic training alone in individuals with coronary artery disease: a meta-analysis[J]. Eur J Prev Cardiol, 2012, 19(1): 81-94. DOI: 10.1177/1741826710393197.
[66]	WILLIAMS M A, HASKELL W L, ADES P A, et al. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism[J]. Circulation, 2007, 116(5): 572-584. DOI: 10.1161/CIRCULATIONAHA.107.185214.
[67]	SCHMIDT T, BJARNASON-WEHRENS B, ZACHER J, et al. Sports, myocarditis and COVID-19: diagnostics, prevention and return-to-play strategies[J]. Int J Sports Med, 2022, 43(13): 1097-1105. DOI: 10.1055/a-1810-5314.
[68]	PRICE K J, GORDON B A, BIRD S R, et al. A review of guidelines for cardiac rehabilitation exercise programmes: is there an international consensus?[J]. Eur J Prev Cardiol, 2016, 23(16): 1715-1733. DOI: 10.1177/2047487316657669.
[69]	RONG J, LI J, JING F S, et al. Efficacy of Baduanjin exercise for rehabilitation after COVID-19: a protocol for systematic review and meta-analysis[J]. Medicine, 2021, 100(24): e26366. DOI: 10.1097/MD.0000000000026366.
[70]	SAENGSIN K, SITTIWANGKUL R, CHATTIPAKORN S C, et al. Hydrogen therapy as a potential therapeutic intervention in heart disease: from the past evidence to future application[J]. Cell Mol Life Sci, 2023, 80(6): 174. DOI: 10.1007/s00018-023-04818-4.
[71]	LEITMAN M, FUCHS S, TYOMKIN V, et al. The effect of hyperbaric oxygen therapy on myocardial function in post-COVID-19 syndrome patients: a randomized controlled trial[J]. Sci Rep, 2023, 13(1): 9473. DOI: 10.1038/s41598-023-36570-x.